Improved outcome at end of treatment in the collaborative Wilms tumour Africa project
dc.contributor.author | Israels, T. | |
dc.contributor.author | Paintsil, V. | |
dc.contributor.author | Nyirenda, D. | |
dc.contributor.author | Kouya, F. | |
dc.contributor.author | Mbah Afungchwi, G. | |
dc.contributor.author | Hesseling, P. | |
dc.contributor.author | Tump, C. | |
dc.contributor.author | Kaspers, G. | |
dc.contributor.author | Burns, L. | |
dc.contributor.author | Singh Arora, R. | |
dc.contributor.author | Chagaluka, G. | |
dc.contributor.author | Nana, P. | |
dc.contributor.author | Renner, L. | |
dc.contributor.author | Molyneux, E. | |
dc.date.accessioned | 2018-10-05T12:31:49Z | |
dc.date.available | 2018-10-05T12:31:49Z | |
dc.date.issued | 2018-01 | |
dc.description.abstract | Background: The Collaborative Wilms Tumour (WT) Africa Project has implemented an adapted WT treatment guideline in sub-Saharan Africa as a multi-centre prospective clinical trial. A retrospective, baseline evaluation of end-of-treatment outcome was performed for a 2-year period prior to the introduction of this guideline. The collaborative project aims to reduce both treatment abandonment and death during treatment to less than 10% for improving survival. Procedure: All participating centres obtained local Institutional Research Board (IRB) approval and implemented the adapted WT treatment guideline. End-of-treatment outcome was documented for 2 years. It was divided into alive without evidence of disease, treatment abandonment, death during treatment and persistent disease. The outcome of children enroled in the first 2 years of the prospective clinical trial has been compared to the outcome before the start of the project. Results: One hundred twenty-two patients were included in the baseline evaluation (2011–2012) and 133 in the first 2 years of the collaborative clinical trial (2014–2015). The percentage of patients alive without evidence of disease at the end of treatment increased from 52% (63/122) to 68% (90/133; P = 0.01). Treatment abandonment decreased from 23% (28/122) to 13% (17/133; P = 0.03). Death during treatment decreased from 21% (26/122) to 13% (17/133; P = 0.07). Conclusion: This collaboration, using relatively simple and low-cost interventions, led to a significant decrease in treatment abandonment and increase in survival without evidence of disease at the end of treatment. © 2018 Wiley Periodicals, Inc. | en_US |
dc.identifier.issn | doi:10.1002/pbc.26945 | |
dc.identifier.uri | http://ugspace.ug.edu.gh/handle/123456789/24519 | |
dc.language.iso | en | en_US |
dc.publisher | John Wiley and Sons Inc. | en_US |
dc.subject | adapted treatment guideline | en_US |
dc.subject | Africa | en_US |
dc.subject | low-income countries | en_US |
dc.subject | regional network | en_US |
dc.subject | survival | en_US |
dc.subject | Wilms tumour | en_US |
dc.title | Improved outcome at end of treatment in the collaborative Wilms tumour Africa project | en_US |
dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.6 KB
- Format:
- Item-specific license agreed upon to submission
- Description: